Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
Crossref DOI link: https://doi.org/10.1007/s13300-022-01300-5
Published Online: 2022-08-05
Published Print: 2022-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shao, Hui
Alsaleh, Abdul Jabbar Omar
Dex, Terry
Lew, Elisheva
Fonseca, Vivian
Funding for this research was provided by:
Sanofi, France
Text and Data Mining valid from 2022-08-05
Version of Record valid from 2022-08-05
Article History
Received: 18 May 2022
Accepted: 15 July 2022
First Online: 5 August 2022